Navigation Links
Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
Date:3/13/2008

------------- -------------

Forward Looking Statements

--------------------------

Statements contained in this press release that are not based on historical fact, including without limitation statements containing the words "believes," "may," "plans," "will," "estimate," "continue," "anticipates," "intends," "expects" and similar expressions, constitute "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and constitute "forward-looking information" within the meaning of applicable Canadian securities laws. All such statements are made pursuant to the "safe harbor" provisions of applicable securities legislation. Forward-looking statements may involve, but are not limited to, comments with respect to our strategies or future actions, our targets, expectations for our financial condition and the results of, or outlook for, our operations, research development and product and drug development. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, events or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions, both nationally and in the regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; adverse results or unexpected delays in drug discovery and clinical development processes; decisions, and the timing of decisions, made by health regulatory agen
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
2. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
3. Angiotech announces results for the fourth quarter ended December 31, 2007
4. Angiotech to participate in Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Angiotech Pharmaceuticals, Inc. - Notice of Conference Call and Webcast
6. Angiotech and Symphony Medical Announce Licensing Agreement
7. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
8. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech to participate in Bank of America 2007 Credit Conference
11. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... REYKJAVIK,Iceland,November24/PRNewswire-FirstCall...edtheapprovalofallofits,"firstday"motionsbytheU.S....uptcyCourt").deCODElastweekfiledavoluntarypetition...yCodewiththe,BankruptcyCourt. , Theordersissu...operateitsbusinessduringtheChapter11proceedings.In...
(Date:11/24/2009)... SEATTLE,Nov.24/PRNewswire/--BlueMarbleEnergyCorp....lopmentAuthority(OPDA)wererecentlyawarded$2million...Board(CERB)inaprivate/publicpartnershiptoconstruct...ncolnCounty,WA. ,, "Thisinvestmentwillsignifica...r70greenjobstoLincolnCounty,"saidBlueMarbleEnergyC...
(Date:11/24/2009)... DUBLIN,November24/PRNewswire-FirstCall/--Shireplc...rmaceuticalcompany,today,announcedthatithassubmitt...ealfa,thecompany,senzymereplacementtherapyindevelo...hethirdmarketing,applicationforvelaglucerasealfath...itedStatesandCanada. , Basedonaglobalsupplysh...
(Date:11/24/2009)... Program Connects Customers with... Collected with DNA Genotek Products , ... -- DNA Genotek , a leading provider of products ...d preparation, today announced its new global part...ements for DNA Genotek,s partner community and is ...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3DNA Genotek Launches Global Partner Program 2DNA Genotek Launches Global Partner Program 3
...v. Jim Doyle has announced new investments desi...ning of engineers in Milwaukee. , ,The investments...aborative research between the Medical College of...illion to help establish a new engineering campus ...500,000 to help design the UWM School of Public He...
... surgical operation requires proper wound closure ...ications, and a Madison start-up business has rece...ves to existing wound-care products. , , Nerites C...dvanced coatings for implanted medical devices, ha...esearch grant. , ,The peer-reviewed grant, which ...
...ue to experience high rates of failure. As a resul...valued partner. The result stifles innovation, gro...turning value to IT requires shedding the flawed p...t create greater alignment between IT and business...oftware. , , Evidence , ,Software development is ...
Other Biology Technology:Doyle outlines spending for Medical College, UWM 2Agile Revolution: A new era of software delivery 2Agile Revolution: A new era of software delivery 3Agile Revolution: A new era of software delivery 4
(Date:11/24/2009)...EW YORK (November 24, 2009) -- The Wildlife Conser...aling that the last remaining population of Siberi... the rising tide of poaching and habitat loss. , ...Russian officials of what needs to be done to prot...at. , The report was released by th...
(Date:11/24/2009)...ovember 24, 2009) New research on bacterial commu...s reveals predictable temporal patterns, suggestin...arkers for monitoring climate change in the polar ...oceedings of the National Academy of Sciences Ear...e six rivers shifted synchronously over time, corr...
(Date:11/23/2009)... The community-associated strain of the deadly sup...to most common antibioticsposes a far greater heal...way into hospitals, according to a study in the De..., The new threat is easily picked up in fitness c...ncreased the overall burden of MRSA within hospita...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Prime Retail Launches Operation Shop Pink 56749 1Prime Retail Launches Operation Shop Pink 56749 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 1Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 4Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 1Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 2Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 3Mpex Pharmaceuticals Announces Positive Phase 2b Clinical Trial Results with Aeroquin 28R 29 28MP 376 29 Treatment in Cystic Fibrosis Patients 13973 4
... 37 abstaining, with 36 absent, the UN today appro...to ban all forms of human cloning, including cloni...an dignity and the protection of human life. , Wh... opposed banning therapeutic cloning. The Declarat...o banned "genetic engineering techniques that may ...
...sistance to the widespread virus, cytomegalovirus ...e of the world,s most prevalent diseases, such as ...reaking research published in Nature Genetics last...uman therapies for CMV, which could prolong the li...splant surgery by reducing the risk of rejection. ...
...ght whales, found during the summer in Alaska wate... populations in the world. Commercial whaling in t...ecently these whales have been recognized as a dif... Atlantic and others in the Southern Hemisphere. ,...itical to the survival of this remnant population ...
Other Biology News:UN votes to ban human cloning 2MUHC scientists describe genetic resistance to rampant virus 2Habitat use by North Pacific right whales, Eubalaena japonica, in the Bering Sea and Gulf of Alaska 2
Rabbit Anti-Human Q96IR3 Polyclonal Antibody, Unconjugated from Atlas Antibodies
12-Tube Magnetic Separation Rack from New England Biolabs
Bromphenol Blue, ACS Reagent from Research Organics, Inc.
Rabbit Anti-Human Q9UPZ6 Polyclonal Antibody, Unconjugated from Atlas Antibodies
Biology Products: